drugset / Trial / NCT04856098

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler

NCT04856098

Phase 1 Completed 34 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelBasic science

Summary

The objective of this study is to assess pharmacokinetics (PK) of indacaterol and glycopyrronium, and methodology and practical arrangements for future studies.

Timeline

Start
2021-05-07
Primary completion
2021-09-21
Completion
2021-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown 43 ug Inhaled
Subject Glycopyrronium Unknown 86 ug Inhaled
Subject Indacaterol Other / unclassified 85 ug Inhaled
Subject Indacaterol Other / unclassified 170 ug Inhaled
Background Activated Charcoal Other / unclassified Oral

Indications

No indication recorded.